

Subt. For, PTO-1449

INFORMATION DISCLOSURE IN AN APPLICATION

(Use several sheets if necessary)

Docket Number
47508-446
(HYZ-050CP2)

Application Number
09/412,947

Applicant
Agrawal

Filing Date
10/05/1999


Group Art Unit
1635

Sheet 1 OF 2


U.S. Patent Documents

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE

Foreign Patent Documents

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
						YES	NO
	WO 91/12323	8/22/91	PCT				
	WO 94/02499	2/3/94	PCT				
	WO 94/07367	4/14/94	PCT				

Other Documents (Including Author, Title, Date Pertinent Pages, Etc.)





	A1	Agrawal, et al.; "Absorption, Tissue Distribution and <i>In Vivo</i> Stability in Rats of a Hybrid Antisense Oligonucleotide Following Oral Administration"; Biochemical Pharmacology; 50(4):571-576 (1995).
	A2	Agrawal, et al; "Comparative Pharmacokinetics of Antisense Oligonucleotides"; in <u>Methods in Molecular Medicine: Antisense Therapeutics</u> (Agrawal, Ed.); pp. 247-270 (1996)
	A3	Agrawal; " <i>In Vivo</i> Pharmacokinetics of Oligonucleotides"; in <u>Applied Antisense Oligonucleotide Technology</u> (Stein and Krieg, Eds.); pp. 365-385 (1998)
	A4	Cho-Chung, et al.; "Protein Kinase-A Directed Antisense Therapy of Tumor Growth <i>In Vivo</i> "; in <u>Methods in Molecular Medicine: Antisense Therapeutics</u> (Agrawal, Ed.); pp. 213-224 (1996)
	A5	Hoke, et al.; "Effects of phosphorothioate capping on antisense oligonucleotide stability, hybridization, and antiviral efficacy versus herpes simplex virus infection"; Nucleic Acids Research; 19(20):5743-5748 (1991).
	A6	Leff; "Italian Oncologists Test Hybridon's Antisense, Molecules in Nude Mice"; BioWorld Today; 8(223):1,4 (1997).
	B1	Lu, et al.; "Chemically Unambiguous Peptide Immunogen: Preparation, Orientation and Antigenicity of Purified Peptide Conjugated to the Multiple Antigen Peptide System"; Molecular Immunology; 28(6):623-630 (1991).


EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation is considered, whether or not citation is in conformance with MPEP § 609: Draw Line through citation if not conformance and not considered. Include copy with next communication to applicant.

Subt. For, PTO-1449				Docket Number 47508-446 (HYZ-050CP2)		Application Number 09/412,947	
INFORMATION DISCLOSURE IN AN APPLICATION <i>(Use several sheets if necessary)</i>				Applicant Agrawal			
				Filing Date 10/05/1999		Group Art Unit 1635	
Sheet	2	OF	2				

	B2	Tortora, et al.; "Synergistic Inhibition of Human Cancer Cell Growth by Cytotoxic Drugs and Mixed Backbone Antisense Oligonucleotide targeting Protein Kinase A"; Proc. Natl. Acad. Sci. USA; 94:12586-12591 (1997).
	B3	Vlassov et al.; "In Vivo Pharmacokinetics of Oligonucleotides Following Administration by Different Routes"; <u>Delivery Strategies for Antisense Oligonucleotide Therapeutics</u> (Akhtar Ed.); CRC Press; pp. 71-83, (1995).
	B4	Zhang, et al.; "Pharmacokinetics of an anti-human immunodeficiency virus antisense oligodeoxynucleotide phosphorothioate (GEM 91) in HIV-infected subjects"; Clinical Pharmacology & Therapeutics; 58(1):44-53 (1995).
	B5	Zhao, et al.; "Comparison of Cellular Binding and Uptake of Antisense Phosphodiester, Phosphorothioate, and Mixed Phosphorothioate and Methylphosphonate Oligonucleotides"; Antisense Research and Development; 3:53-66 (1993).
	B6	
	B7	
	B8	
	B9	
	B10	
	B11	
	B12	
	B13	
	B14	
	B15	
	C1	
	C2	
	C3	
	C4	
	C5	
	C6	
	C7	
	C8	
	C9	
	C10	
	C11	
	C12	
	C13	
	C14	
	C15	
	C16	
	C17	
	D1	

EXAMINER		DATE CONSIDERED	1-24-03
EXAMINER: Initial if citation is considered, whether or not citation is in conformance with MPEP § 609: Draw Line through citation if not conformance and not considered. Include copy with next communication to applicant.			